CytoTools AG received a trading update on the first quarter of 2021 from its licensing partner Centaur Pharmaceuticals on the drug Woxheal(R) for the treatment of the Diabetic Foot Syndrome. According to the update, despite significant pandemic-related sales hinderances, sales of Woxheal(R) in India have increased slightly to over 10,000 use cases compared to the fourth quarter of 2020. In addition, Centaur Pharmaceuticals has informed the Company that it has now received tentative approval for Woxheal(R) in Kenya, Africa. Provisional approval of a drug can be granted in Kenya without additional studies based on the approval of the India Central Drugs Standard Control Organization (CDSCO). In parallel, Centaur is seeking approval for the drug in other African countries where a basically similar approval process is possible. Despite delays due to the progress of COVID-19 in Europe, the Management Board assesses the current progress of the study as still on track. Therefore, the company still expects to be able to report interim results of the study at the end of 2021 and then to successfully complete Phase III by the end of 2022.